Entera Bio Ltd. (ENTX)

IL — Healthcare Sector
Peers: ANIX  VTGN  IRD  SEER  HURA  ABOS  MCRB  SPRO  AGEN  INO 

Automate Your Wheel Strategy on ENTX

With Tiblio's Option Bot, you can configure your own wheel strategy including ENTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ENTX
  • Rev/Share 0.0026
  • Book/Share 0.3235
  • PB 5.8113
  • Debt/Equity 0.0139
  • CurrentRatio 10.8256
  • ROIC -0.1534

 

  • MktCap 86198502.0
  • FreeCF/Share 0.0101
  • PFCF 181.4709
  • PE -35.3691
  • Debt/Assets 0.0121
  • DivYield 0
  • ROE -0.167

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
ENTX
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections

Read More
image for news Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)
Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
ENTX
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company's Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference, details as below.

Read More
image for news Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
ENTX
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive

ENTX posts positive PK data for its first oral GLP-2 therapy, signaling a potential breakthrough in short bowel syndrome treatment.

Read More
image for news Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy

About Entera Bio Ltd. (ENTX)

  • IPO Date 2018-06-28
  • Website https://www.enterabio.com
  • Industry Biotechnology
  • CEO Miranda J. Toledano
  • Employees 18
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.